The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study

The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study

Abstract Background AVERT-2 (a phase IIIb, two-stage study) evaluated abatacept + methotrexate versus methotrexate alone, in methotrexate-naive, anti-citrullinated protein antibody-positive patients with early (≤ 6 months), active RA. This subanalysis investigated whether individual patients who ach...

Full description

Bibliographic Details
Main Authors: Paul Emery, Yoshiya Tanaka, Vivian P. Bykerk, Clifton O. Bingham, Thomas W. J. Huizinga, Gustavo Citera, Kuan-Hsiang Gary Huang, Chun Wu, Sean E. Connolly, Yedid Elbez, Robert Wong, Karissa Lozenski, Roy Fleischmann
Format: Article
Language:English
Published: BMC 2023-04-01
Series:Arthritis Research & Therapy
Subjects:
Rheumatoid arthritis
Anti-citrullinated protein antibody
Sustained remission
Abatacept
Online Access:https://doi.org/10.1186/s13075-023-03038-2

Internet

https://doi.org/10.1186/s13075-023-03038-2

Similar Items